156 related articles for article (PubMed ID: 23874525)
81. Causal relationship between Alzheimer's disease and prostate cancer: a bidirectional Mendelian randomization analysis.
Li R; Peng L; Deng D; Li G; Wu S
Front Endocrinol (Lausanne); 2024; 15():1354528. PubMed ID: 38544686
[TBL] [Abstract][Full Text] [Related]
82. Causal association between colorectal cancer and Alzheimer's disease: a bidirectional two-sample mendelian randomization study.
Yuan C; Liu S; Yang K; Xie F; Li Y; Guo Y; Zhao W; Zhang J; Cheng Z
Front Genet; 2023; 14():1180905. PubMed ID: 38250575
[No Abstract] [Full Text] [Related]
83. Stabilization of Pin1 by USP34 promotes Ubc9 isomerization and protein sumoylation in glioma stem cells.
Zhu Q; Liang P; Meng H; Li F; Miao W; Chu C; Wang W; Li D; Chen C; Shi Y; Yu X; Ping Y; Niu C; Wu HB; Zhang A; Bian XW; Zhou W
Nat Commun; 2024 Jan; 15(1):40. PubMed ID: 38167292
[TBL] [Abstract][Full Text] [Related]
84. Association between cancer and dementia risk in the UK Biobank: evidence of diagnostic bias.
Wang J; Buto P; Ackley SF; Kobayashi LC; Graff RE; Zimmerman SC; Hayes-Larson E; Mayeda ER; Asiimwe SB; Calmasini C; Glymour MM
Eur J Epidemiol; 2023 Oct; 38(10):1069-1079. PubMed ID: 37634228
[TBL] [Abstract][Full Text] [Related]
85. Proline Isomerization: From the Chemistry and Biology to Therapeutic Opportunities.
Gurung D; Danielson JA; Tasnim A; Zhang JT; Zou Y; Liu JY
Biology (Basel); 2023 Jul; 12(7):. PubMed ID: 37508437
[TBL] [Abstract][Full Text] [Related]
86. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
Koikawa K; Kibe S; Suizu F; Sekino N; Kim N; Manz TD; Pinch BJ; Akshinthala D; Verma A; Gaglia G; Nezu Y; Ke S; Qiu C; Ohuchida K; Oda Y; Lee TH; Wegiel B; Clohessy JG; London N; Santagata S; Wulf GM; Hidalgo M; Muthuswamy SK; Nakamura M; Gray NS; Zhou XZ; Lu KP
Cell; 2021 Sep; 184(18):4753-4771.e27. PubMed ID: 34388391
[TBL] [Abstract][Full Text] [Related]
87. Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo.
Dubiella C; Pinch BJ; Koikawa K; Zaidman D; Poon E; Manz TD; Nabet B; He S; Resnick E; Rogel A; Langer EM; Daniel CJ; Seo HS; Chen Y; Adelmant G; Sharifzadeh S; Ficarro SB; Jamin Y; Martins da Costa B; Zimmerman MW; Lian X; Kibe S; Kozono S; Doctor ZM; Browne CM; Yang A; Stoler-Barak L; Shah RB; Vangos NE; Geffken EA; Oren R; Koide E; Sidi S; Shulman Z; Wang C; Marto JA; Dhe-Paganon S; Look T; Zhou XZ; Lu KP; Sears RC; Chesler L; Gray NS; London N
Nat Chem Biol; 2021 Sep; 17(9):954-963. PubMed ID: 33972797
[TBL] [Abstract][Full Text] [Related]
88. Association Between Alzheimer Disease and Cancer With Evaluation of Study Biases: A Systematic Review and Meta-analysis.
Ospina-Romero M; Glymour MM; Hayes-Larson E; Mayeda ER; Graff RE; Brenowitz WD; Ackley SF; Witte JS; Kobayashi LC
JAMA Netw Open; 2020 Nov; 3(11):e2025515. PubMed ID: 33185677
[TBL] [Abstract][Full Text] [Related]
89. Post-translational Modifications of the Peptidyl-Prolyl Isomerase Pin1.
Chen D; Wang L; Lee TH
Front Cell Dev Biol; 2020; 8():129. PubMed ID: 32195254
[TBL] [Abstract][Full Text] [Related]
90. Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis.
Chen L; Xu X; Wen X; Xu S; Wang L; Lu W; Jiang M; Huang J; Yang D; Wang J; Zheng M; Zhou XZ; Lu KP; Liu H
Cancer Sci; 2019 Aug; 110(8):2442-2455. PubMed ID: 31148345
[TBL] [Abstract][Full Text] [Related]
91. A Guide to PIN1 Function and Mutations Across Cancers.
El Boustani M; De Stefano L; Caligiuri I; Mouawad N; Granchi C; Canzonieri V; Tuccinardi T; Giordano A; Rizzolio F
Front Pharmacol; 2018; 9():1477. PubMed ID: 30723410
[TBL] [Abstract][Full Text] [Related]
92. The Multiple Roles of Peptidyl Prolyl Isomerases in Brain Cancer.
Stifani S
Biomolecules; 2018 Oct; 8(4):. PubMed ID: 30314361
[TBL] [Abstract][Full Text] [Related]
93. A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways.
Yang D; Luo W; Wang J; Zheng M; Liao XH; Zhang N; Lu W; Wang L; Chen AZ; Wu WG; Liu H; Wang SB; Zhou XZ; Lu KP
J Control Release; 2018 Jan; 269():405-422. PubMed ID: 29170140
[TBL] [Abstract][Full Text] [Related]
94. MicroRNA-140-5p inhibits hepatocellular carcinoma by directly targeting the unique isomerase Pin1 to block multiple cancer-driving pathways.
Yan X; Zhu Z; Xu S; Yang LN; Liao XH; Zheng M; Yang D; Wang J; Chen D; Wang L; Liu X; Liu J; Chen RH; Zhou XZ; Lu KP; Liu H
Sci Rep; 2017 Apr; 7():45915. PubMed ID: 28383568
[TBL] [Abstract][Full Text] [Related]
95. The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target.
Zhou XZ; Lu KP
Nat Rev Cancer; 2016 Jul; 16(7):463-78. PubMed ID: 27256007
[TBL] [Abstract][Full Text] [Related]
96. Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer.
Wei S; Kozono S; Kats L; Nechama M; Li W; Guarnerio J; Luo M; You MH; Yao Y; Kondo A; Hu H; Bozkurt G; Moerke NJ; Cao S; Reschke M; Chen CH; Rego EM; Lo-Coco F; Cantley LC; Lee TH; Wu H; Zhang Y; Pandolfi PP; Zhou XZ; Lu KP
Nat Med; 2015 May; 21(5):457-66. PubMed ID: 25849135
[TBL] [Abstract][Full Text] [Related]
97. Prolyl isomerase Pin1 in cancer.
Lu Z; Hunter T
Cell Res; 2014 Sep; 24(9):1033-49. PubMed ID: 25124924
[TBL] [Abstract][Full Text] [Related]
98. The rs2233678 polymorphism in PIN1 promoter region reduced cancer risk: a meta-analysis.
Li Q; Dong Z; Lin Y; Jia X; Li Q; Jiang H; Wang L; Gao Y
PLoS One; 2013; 8(7):e68148. PubMed ID: 23874525
[TBL] [Abstract][Full Text] [Related]
99. Association of rs2233678 and rs2233679 polymorphisms in the PIN1 gene with cancer risk: a meta-analysis.
Zhenzhen L; Ning S; Xianghua L
Tumour Biol; 2014 Jan; 35(1):433-40. PubMed ID: 23982872
[TBL] [Abstract][Full Text] [Related]
100. Single nucleotide polymorphisms of PIN1 promoter region and cancer risk: evidence from a meta-analysis.
Peng JJ; Wei D; Li D; Fu ZQ; Tan Y; Xu T; Zhou JJ; Zhang T
PLoS One; 2013; 8(8):e70990. PubMed ID: 23976970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
